| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TOR3A |
| Uniprot No | Q9H497 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-397aa |
| 氨基酸序列 | ASRPW EGTDEPGSAW AWPGFQRLQE QLRAAGALSK RYWTLFSCQV WPDDCDEDEE AATGPLGWRL PLLGQRYLDL LTTWYCSFKD CCPRGDCRIS NNFTGLEWDL NVRLHGQHLV QQLVLRTVRG YLETPQPEKA LALSFHGWSG TGKNFVARML VENLYRDGLM SDCVRMFIAT FHFPHPKYVD LYKEQLMSQI RETQQLCHQT LFIFDEAEKL HPGLLEVLGP HLERRAPEGH RAESPWTIFL FLSNLRGDII NEVVLKLLKA GWSREEITME HLEPHLQAEI VETIDNGFGH SRLVKENLID YFIPFLPLEY RHVRLCARDA FLSQELLYKE ETLDEIAQMM VYVPKEEQLF SSQGCKSISQ RINYFLS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TOR3A重组蛋白的3篇代表性文献的简要信息：
1. **文献名称**：Structural and functional analysis of human TOR3A ATPase
**作者**：Smith J, et al.
**摘要**：本研究解析了重组人源TOR3A蛋白的晶体结构，揭示其ATP结合域的构象变化机制，并验证其在内质网应激反应中的调控作用，为神经退行性疾病相关突变研究提供结构基础。
2. **文献名称**：Recombinant TOR3A interacts with nuclear pore proteins in vitro
**作者**：Wang L, et al.
**摘要**：通过重组表达纯化TOR3A蛋白，发现其与核孔复合物蛋白NUP155存在直接互作，提示TOR3A可能参与核膜稳定性和核质运输的调控通路。
3. **文献名称**：TOR3A overexpression ameliorates α-synuclein aggregation in Parkinson’s disease models
**作者**：Garcia R, et al.
**摘要**：利用重组TOR3A蛋白进行体外实验，发现其通过增强分子伴侣活性抑制α-突触核蛋白异常聚集，为帕金森病的潜在治疗靶点提供证据。
注：以上文献为领域典型研究方向示例，实际文献需通过PubMed/Google Scholar等平台检索确认。
TOR3A (Torsin family 3 member A) is a member of the Torsin family of ATPases, which belong to the AAA+ (ATPases Associated with diverse cellular Activities) superfamily. These proteins are characterized by their conserved ATP-binding and hydrolysis domains, enabling energy-dependent conformational changes critical for their functions. TOR3A is primarily localized to the endoplasmic reticulum (ER) and nuclear envelope, where it interacts with other Torsin proteins (e.g., TOR1A, TOR2A) and cofactors like LAP1 and LULL1. Unlike its well-studied paralog TOR1A (mutations in which cause early-onset dystonia), TOR3A remains less characterized but shares structural homology and putative roles in membrane remodeling, protein trafficking, and ER stress response.
Research suggests TOR3A may contribute to cellular processes such as nuclear envelope integrity, vesicular transport, and quality control of misfolded proteins. Its involvement in ER-associated degradation (ERAD) pathways highlights potential links to neurodegenerative diseases and cancer. Notably, TOR3A expression is upregulated under stress conditions, implying a protective role in maintaining cellular homeostasis. However, its exact molecular mechanisms and physiological significance are still under investigation.
Recombinant TOR3A protein is engineered for in vitro studies, typically expressed in bacterial or mammalian systems with affinity tags (e.g., His-tag) for purification. It serves as a tool to explore ATPase activity, protein-protein interactions, and structural features via techniques like X-ray crystallography or cryo-EM. Recent studies also investigate its potential as a therapeutic target, particularly in diseases involving ER dysfunction. Despite progress, functional redundancy within the Torsin family and the lack of disease-associated mutations in TOR3A pose challenges in delineating its unique contributions to cellular physiology. Ongoing research aims to unravel its role in health and disease, leveraging recombinant protein technology to bridge knowledge gaps.
×
